24-hour Intraocular Pressure (IOP) Control With the Bimatoprost/Timolol Fixed Combination
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The objective of this crossover, randomized, placebo controlled, double-masked study is to
compare the short-term (12 weeks) mean 24-hour IOP control and safety of the new fixed
combination (bimatoprost/timolol, BTFC) given PM with placebo once in the morning, versus
BTFC given AM with placebo once in the evening versus bimatoprost given in the evening in
patients with exfoliative glaucoma (XFG).